Oncology Today with Dr Neil Love Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Nov 26, 2025
Dr. Priyanka Sharma, a medical oncologist from The University of Kansas Cancer Center, delves into the latest breast cancer treatment innovations. She highlights promising results from the Destiny Breast 05 study, showcasing a significant reduction in disease events with TDXD. Discussions include the safety concerns of pneumonitis, the impact of new therapies on brain metastasis, and insights from ongoing trials like COMPASS HER2-RD. Sharma emphasizes the importance of quality-of-life considerations and future maintenance strategies for patients.
AI Snips
Chapters
Transcript
Episode notes
TDXD Markedly Improves IDFS In High-Risk Residual Disease
- Trastuzumab deruxtecan (TDXD) reduced risk of invasive disease recurrence or death by 53% versus T-DM1 in high-risk HER2+ residual disease after neoadjuvant therapy.
- The absolute 3-year IDFS improvement was 8.7%, with 92% IDFS on TDXD versus ~84% on T-DM1.
Screen And Avoid In Patients With Lung Issues
- Monitor patients carefully for interstitial lung disease because TDXD carries a real pneumonitis/ILD risk and the trial used regular CT scanning.
- Avoid TDXD in patients with preexisting lung issues or prior pneumonitis when possible.
Potential CNS Advantage Over T-DM1
- TDXD showed numerically fewer brain metastases than T-DM1, suggesting CNS benefit consistent with metastatic data.
- This aligns with prior metastatic experience where TDXD improved intracranial activity compared with older ADCs.